Consensus Structure Therapeutics Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
35.82 ^USD	-7.32%		-8.83%	-12.12%

May. 09	Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target	MT

24a85b07de.KbkmVgUEN0n6cMbCC0fV0CxuW0uomksoEv1nwz7UAFk.UY5VLG1GQDyMMqGqeS-UmHUfaTrrwhhsRbYRmnWQeC5Q7WEDYjBVGJ8l9g~6c207230f10835e62744e4a3606892e3

Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target	Apr. 09	MT
JMP Securities Adjusts Structure Therapeutics' Price Target to $91 From $90, Keeps Market Outperform Rating	Nov. 15	MT
Piper Sandler Raises Price Target on Structure Therapeutics to $93 From $58, Maintains Overweight Rating	23-10-27	MT
JMP Securities Starts Coverage on Structure Therapeutics with Market Outperform Rating, $90 Price Target	23-10-19	MT
BMO Capital Adjusts Structure Therapeutics Price Target to $83 From $40, Maintains Outperform Rating	23-10-03	MT
Piper Sandler Initiates Structure Therapeutics With Overweight Rating, $58 Price Target	23-07-27	MT
SVB Securities Initiates Structure Therapeutics at Outperform Rating With $33 Price Target	23-02-28	MT
BMO Capital Initiates Structure Therapeutics at Outperform With $40 Price Target	23-02-28	MT
Jefferies Initiates Structure Therapeutics at Buy With $34 Price Target	23-02-28	MT
Guggenheim Starts Structure Therapeutics at Buy With $50 Price Target	23-02-28	MT
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data	23-02-13	RE

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.82 USD

Average target price

76.89 USD

Spread / Average Target

+114.65%

High Price Target

93 USD

Spread / Highest target

+159.63%

Low Price Target

48 USD

Spread / Lowest Target

+34.00%